The Pharmacy Times® Atopic Dermatitis Resource Center is a comprehensive resource for clinical news and expert insights on treatments for atopic dermatitis.
March 13th 2024
Findings originate from phase 3 data that was recently presented at the 2024 American Academy of Dermatology (AAD) Annual Meeting.
FDA Approves Expanded Indication for Abrocitinib to Include Adolescents With Atopic Dermatitis
February 13th 2023Expanded indication for abrocitinib (Cibinqo; Pfizer Inc) includes patients 12 to <18 years of age with refractory, moderate-to-severe atopic dermatitis that is not adequately controlled with other systemic medications.
Read More
Phase 3 Data Favor Bimekizumab Over Placebo in Biologic-Naïve Patients With Psoriatic Arthritis
December 20th 2022All primary and ranked secondary endpoints of the study were met at week 16, which were sustained or improved through week 24 and were coupled with patient-reported improvements compared with placebo in treating psoriatic arthritis.
Read More
Lebrikuzumab Found to Maintain Durable Skin Clearance When Dosed Every 4 Weeks in Atopic Dermatitis
September 14th 2022ADvocate 1 and ADvocate 2 are 52-week randomized, double-blind phase 3 studies designed to evaluate lebrikizumab as monotherapy in adult and adolescent patients with moderate to severe AD.
Read More